Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
Details : CA-4948 (emavusertib) is an IRAK4/FLT3/CLK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with Refractory Primary Central Nervous System Lymphoma.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 12, 2023
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University of Florida
Deal Size : Undisclosed
Deal Type : Agreement
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
Details : Under the terms of the agreement, Curis will supply emavusertib and Merck will supply pembrolizumab & bear the costs for clinical study of the novel combination of CA-4948 (emavusertib) and pembrolizumab (anti-PD1) in metastatic melanoma.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2023
Lead Product(s) : Emavusertib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Florida
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cantor Fitzgerald & Co.
Deal Size : $15.1 million
Deal Type : Public Offering
Curis Announces $15.1 Million Registered Direct Offering
Details : Curis intends to use the net proceeds from the offering on research and development of CA-4948 (emavusertib), an Oral, small molecule IRAK4 kinase inhibitor, being developed for the treatment of Leukemia.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cantor Fitzgerald & Co.
Deal Size : $15.1 million
Deal Type : Public Offering
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
Details : CA-4948 (emavusertib) is a triple target inhibitor (IRAK4, FLT3 and CLK), which is investiated for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2023
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Aurigene
Deal Size : Not Applicable
Deal Type : Not Applicable
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
Details : With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of...
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2023
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Aurigene
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Emavusertib (CA-4948) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2022
Lead Product(s) : Emavusertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
Details : CA-4948 (emavusertib) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2022
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University of Florida
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CA-4948 (emavusertib), is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2022
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Florida
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TakeAim Lymphoma data for the combination of CA-4948 (emavusertib) plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 04, 2022
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data from TakeAim Leukemia study are consistent with our findings demonstrated CA-4948 (emavusertib) encouraging monotherapy activity in patients with R/R AML and MDS including importantly those with spliceosome and FLT3 mutations.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 12, 2022
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?